SyntekaBio

SyntekaBio Stock-Based Compensation

The Stock-Based Compensation (SBC) of SyntekaBio (226330.KQ) as of Nov 20, 2026 is 625.00 M KRW. In the previous year, Stock-Based Compensation (SBC) was 572.84 M KRW — a change of 9.11% (higher).

Stock-Based Compensation

625.00 MKRW

YoY

9.11%

Last updated:

Stock-Based Compensation (SBC) of SyntekaBio is 2025 625.00 M KRW. Stock-Based Compensation (SBC) of SyntekaBio was 2024 572.84 M KRW. It decreases by 9.11% higher compared to the previous year.

The SyntekaBio Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2020
568.15 M KRW
Jan 1, 2021
364.78 M KRW
Jan 1, 2022
793.17 M KRW
Jan 1, 2023
779.78 M KRW
Jan 1, 2024
572.84 M KRW
Jan 1, 2025
625.00 M KRW
The SyntekaBio Stock-Based Compensation history
YEARStock-Based CompensationYoY
625.00 MKRW+9.11%
572.84 MKRW-26.54%
779.78 MKRW-1.69%
793.17 MKRW+117.44%
364.78 MKRW-35.80%
568.15 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SyntekaBio Stock analysis

What does SyntekaBio do? SyntekaBio Inc. provides bioinformatics solutions through AI-driven software and services. The company develops and sells PMAP, a personal algorithm dielectric map platform using artificial intelligence, and offers clinical trial modeling and genome analysis services via big data. These services diagnose genetic diseases, select biomarker treatments, and predict disease risk. SyntekaBio also develops AI drug development technology and provides research services for candidate substances of immuno-cancer drugs. The primary customers for SyntekaBio's products include healthcare providers, research institutions, and pharmaceutical companies. Healthcare providers use the diagnostic and predictive services for patient care, while research institutions and pharmaceutical firms utilize the genome analysis and drug development technologies. The company's AI-driven tools are tailored to meet the needs of these segments, focusing on precision medicine and oncology applications. SyntekaBio's revenue streams come from software sales, service contracts for clinical trial modeling and genome analysis, and research services for immuno-cancer drug candidates. The company's AI drug development technology is a key offering, targeting pharmaceutical companies seeking to accelerate drug discovery and development processes. The firm's focus on AI and big data analytics positions it as a provider of specialized solutions in the bioinformatics sector. SyntekaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SyntekaBio stock

Stock-Based Compensation (SBC) of SyntekaBio is 625.00 M KRW in 2025.

Stock-Based Compensation (SBC) of SyntekaBio changed from 572.84 M KRW to 625.00 M KRW, representing a 9.11% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) SyntekaBio since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s SyntekaBio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — SyntekaBio

All Key Metrics — SyntekaBio